The inventor of base and prime editing shares insights on medicine's efforts to make serious genetic diseases treatable or ...

Cellectis (the 'Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds.

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Precision gene editing can be achieved by base editing, nucleotide editing, or editing of small or large gene fragments. The specific mechanisms include various DNA repair pathways. Many precision ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.